Why the study?
Does Brain natriuretic peptide (BNP) testing improve the diagnosis and exclusion of congestive heart failure in acutely ill patients presenting to the emergency department with dyspnea?
Does Brain natriuretic peptide (BNP) testing improve the diagnosis and exclusion of congestive heart failure in acutely ill patients presenting to the emergency department with dyspnea?
BNP serves as a valuable biochemical marker to aid in the rapid diagnosis and exclusion of congestive heart failure in emergency department patients with acute dyspnea.
Supports BNP testing for HF diagnosis in acute dyspnea; leaves open prospective outcome trials before routine adoption.
For the acutely ill patients who present to the emergency department (ED) with dyspnea, an incorrect or delayed diagnosis of congestive heart failure (CHF) could place the patient at an increased risk for both morbidity and mortality. Therefore, a rapid and accurate diagnosis of CHF is mandatory for administering appropriate and efficacious management. Unfortunately, the signs and symptoms, and readily available emergency diagnostics are neither sensitive nor specific enough for diagnosing CHF alone. Brain natriuretic peptide (BNP) is secreted by myocytes in response to ventricular stretch and it has long been thought that BNP could become a biochemical marker for CHF and could be a useful tool in the diagnosis and exclusion of CHF if it is applied appropriately. (Korean Circulation J 2007;37:464-469)
No takes yet. Share an insight, caveat, or question.
Ji Yong Choi (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: